COMMUNIQUÉS West-GlobeNewswire

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
04/06/2025
June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical [...]
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
04/06/2025
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market [...]
Synergy CHC Announces New $20 Million Long-Term Credit Facility
04/06/2025
WESTBROOK, Maine, June 04, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, announced today that it has entered into a $ [...]
ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance
04/06/2025
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its [...]
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
04/06/2025
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- [...]
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
04/06/2025
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement [...]
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)
04/06/2025
Annamycin delivering better performance 7 th line than would be expected even in 2 nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and [...]
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
04/06/2025
New 8-count bottles now available through major retail pharmacies ARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June 04, 2025 (GLOBE [...]
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
04/06/2025
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems Southlake, TX, June 04, 2025 (GLOBE NEWSWIRE [...]
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma
04/06/2025
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma Paris, France, June 4 th , 2025 . Oncovita, a biotechnology company developing [...]
Highridge Medical Completes the Sale of its Bone Healing Division to Streamline Strategic Focus and Innovation in Spine
04/06/2025
Sale proceeds will accelerate investment in portfolio innovation and commercial expansion for Spine. WESTMINSTER, Colo., June 04, 2025 (GLOBE NEWSWIRE) -- Highridge Medical (“Highridge” or the “Company”), one of the [...]
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
04/06/2025
Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet [...]
TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors
04/06/2025
- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with KRAS-G12C-mutant NSCLC, EGFR- [...]
Accumulus Synergy et Veeva Systems s’associent afin d’accélérer la transformation réglementaire et la connectivité
04/06/2025
BURLINGAME, Calif., 04 juin 2025 (GLOBE NEWSWIRE) -- Accumulus Synergy (« Accumulus ») a annoncé aujourd’hui un partenariat stratégique avec Veeva Systems (« Veeva ») axé sur la mise en place de solutions de [...]
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation and Connectivity
04/06/2025
BURLINGAME, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Today, Accumulus Synergy (“Accumulus”) announced a strategic partnership with Veeva Systems (“Veeva”) focused on enabling connectivity to help the life sciences [...]
Revive Therapeutics Advances with Next-Generation Bucillamine Development
04/06/2025
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative [...]
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
04/06/2025
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to [...]
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
04/06/2025
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46 th Annual Global Healthcare Conference on Wednesday, [...]
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
04/06/2025
Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle [...]

Pages